A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2016; you can also visit the original URL.
The file type is
not need an alloSCT for cure after relapse. Results of the ongoing International BFM Study Group Pediatric Relapsed AML protocol, will contribute to this discussion in the near future. The Dutch and literature data suggest that randomized studies of the role of alloSCT in subgroups of relapsed AML are required. Meanwhile, experimental allogeneic SCT procedures, such as haplo-identical and mismatched unrelated donor SCT, should be carefully balanced against the chance of cure by chemotherapydoi:10.3324/haematol.12846 pmid:18641029 fatcat:rmtwbg26ovbyxlt35d5lxgvg6i